Indoco Remedies Limited — Investor Meet, 26-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Indoco Remedies has announced a board meeting on 7th June 2025 to consider the financial results for the quarter and half-year.

Standalone revenue declined to INR149.48 Cr (vs INR176.20 Cr), with EBITDA margin at 8.6% (down from 14.6%). Consolidated revenue fell to INR164.13 Cr (vs INR178.82 Cr) and EBITDA margin slipped to 6%. Challenges included manufacturing delays and a U.S. FDA warning affecting sterile plant supplies. Domestic formulations grew 8.5%, led by vitamins and gastro segments, while international sales dropped sharply. API business grew to INR40.9 Cr from INR21.7 Cr. Management expects international operations to recover from Q2 FY ’26, with gradual margin improvement and steady R&D focus. Debt remains around INR960 Cr, with organic repayment plans. Sentiment is cautiously optimistic amid operational recovery.